查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1487561

風濕病治療市場（藥物類別：改變疾病的抗風濕藥、非類固醇抗發炎藥、皮質類固醇、尿酸藥物等）-全球產業分析、規模、佔有率、成長、趨勢和預測，2024-2034

Rheumatology Therapeutics Market (Drug Class: Disease Modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 205 Pages | 商品交期: 2-10個工作天內

價格

風濕病治療市場 - 報告範圍

TMR 關於全球風濕病治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2024 年至 2034 年預測期內市場指標的寶貴見解。年期間，考慮2024年為基準年，2034年為預測年。該報告也提供了2024年至2034年全球風濕病治療市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解風濕病治療市場。

市場概況
2023年市場價值 488 億美元
2034 年市場價值 651 億美元
複合年成長率 2.6%

該報告深入探討了全球風濕病治療市場的競爭格局。全球風濕病治療市場的主要參與者已經確定，並且每位參與者都根據不同的屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球風濕病治療市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2020-2034年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依藥物類別

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依藥品類別，2020-2034
    • 疾病緩解抗風濕藥物 (DMARD)
      • 合成疾病緩解抗風濕藥物
      • 生物疾病緩解抗風濕藥物
    • 非類固醇類抗發炎藥 (NSAID)
    • 皮質類固醇
    • 降尿酸藥物
    • 其他
  • 市場吸引力：按藥品類別

第 7 章：全球市場分析與預測：按疾病適應症

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依疾病適應症，2020-2034
    • 類風濕關節炎
    • 骨關節炎
    • 痛風
    • 銀屑病關節炎
    • 僵直性脊椎炎
    • 其他
  • 市場吸引力：依疾病適應症分類

第 8 章：全球市場分析與預測：依給藥途徑

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依給藥途徑，2020-2034年
    • 腸外途徑
    • 口頭途徑
    • 專題
  • 市場吸引力：依給藥途徑分類

第 9 章：全球市場分析與預測：按配銷通路

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2020-2034
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 市場吸引力：按配銷通路分類

第 10 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020-2034
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 11 章：北美市場分析與預測

第 12 章：歐洲市場分析與預測

第 13 章：亞太市場分析與預測

第 14 章：拉丁美洲市場分析與預測

第 15 章：中東和非洲市場分析與預測

第16章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2023）
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
    • AbbVie, Inc.
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Amgen, Inc.
    • Genentech, Inc.
    • Novartis AG
    • Johnson & Johnson Innovative Medicine
    • Sanofi
    • Merck & Co., Inc.
Product Code: TMRGL1494

Rheumatology Therapeutics Market - Scope of Report

TMR's report on the global rheumatology therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global rheumatology therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global rheumatology therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the rheumatology therapeutics market.

Market Snapshot
Market Value in 2023US$ 48.8 Bn
Market Value in 2034US$ 65.1 Bn
CAGR2.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global rheumatology therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global rheumatology therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global rheumatology therapeutics market.

The report delves into the competitive landscape of the global rheumatology therapeutics market. Key players operating in the global rheumatology therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global rheumatology therapeutics market profiled in this report.

Key Questions Answered in Global rheumatology therapeutics Market Report:

  • What is the sales/revenue generated by rheumatology therapeutics across all regions during the forecast period?
  • What are the opportunities in the global rheumatology therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Rheumatology Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global rheumatology therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global rheumatology therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global rheumatology therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Rheumatology Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Rheumatology Therapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 6.3.3. Corticosteroids
    • 6.3.4. Uric Acid Drugs
    • 6.3.5. Others
  • 6.4. Market Attractiveness, by Drug Class

7. Global Rheumatology Therapeutics Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2020-2034
    • 7.3.1. Rheumatoid Arthritis
    • 7.3.2. Osteoarthritis
    • 7.3.3. Gout
    • 7.3.4. Psoriatic Arthritis
    • 7.3.5. Ankylosing Spondylitis
    • 7.3.6. Others
  • 7.4. Market Attractiveness, by Disease Indication

8. Global Rheumatology Therapeutics Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 8.3.1. Parenteral Route
    • 8.3.2. Oral Route
    • 8.3.3. Topical
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Rheumatology Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global Rheumatology Therapeutics Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Rheumatology Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2020-2034
    • 11.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 11.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 11.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 11.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 11.2.3. Corticosteroids
    • 11.2.4. Uric Acid Drugs
    • 11.2.5. Others
  • 11.3. Market Attractiveness, by Drug Class
  • 11.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 11.4.1. Rheumatoid Arthritis
    • 11.4.2. Osteoarthritis
    • 11.4.3. Gout
    • 11.4.4. Psoriatic Arthritis
    • 11.4.5. Ankylosing Spondylitis
    • 11.4.6. Others
  • 11.5. Market Attractiveness, by Disease Indication
  • 11.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.6.1. Parenteral Route
    • 11.6.2. Oral Route
    • 11.6.3. Topical
  • 11.7. Market Attractiveness, by Route of Administration
  • 11.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.8.1. Hospital Pharmacy
    • 11.8.2. Retail Pharmacy
    • 11.8.3. Online Pharmacy
  • 11.9. Market Attractiveness, by Distribution Channel
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Drug Class
    • 11.11.2. By Disease Indication
    • 11.11.3. By Route of Administration
    • 11.11.4. By Distribution Channel
    • 11.11.5. By Country

12. Europe Rheumatology Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2020-2034
    • 12.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 12.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 12.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 12.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 12.2.3. Corticosteroids
    • 12.2.4. Uric Acid Drugs
    • 12.2.5. Others
  • 12.3. Market Attractiveness, by Drug Class
  • 12.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 12.4.1. Rheumatoid Arthritis
    • 12.4.2. Osteoarthritis
    • 12.4.3. Gout
    • 12.4.4. Psoriatic Arthritis
    • 12.4.5. Ankylosing Spondylitis
    • 12.4.6. Others
  • 12.5. Market Attractiveness, by Disease Indication
  • 12.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.6.1. Parenteral Route
    • 12.6.2. Oral Route
    • 12.6.3. Topical
  • 12.7. Market Attractiveness, by Route of Administration
  • 12.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.8.1. Hospital Pharmacy
    • 12.8.2. Retail Pharmacy
    • 12.8.3. Online Pharmacy
  • 12.9. Market Attractiveness, by Distribution Channel
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Drug Class
    • 12.11.2. By Disease Indication
    • 12.11.3. By Route of Administration
    • 12.11.4. By Distribution Channel
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Rheumatology Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2020-2034
    • 13.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 13.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 13.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 13.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 13.2.3. Corticosteroids
    • 13.2.4. Uric Acid Drugs
    • 13.2.5. Others
  • 13.3. Market Attractiveness, by Drug Class
  • 13.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 13.4.1. Rheumatoid Arthritis
    • 13.4.2. Osteoarthritis
    • 13.4.3. Gout
    • 13.4.4. Psoriatic Arthritis
    • 13.4.5. Ankylosing Spondylitis
    • 13.4.6. Others
  • 13.5. Market Attractiveness, by Disease Indication
  • 13.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.6.1. Parenteral Route
    • 13.6.2. Oral Route
    • 13.6.3. Topical
  • 13.7. Market Attractiveness, by Route of Administration
  • 13.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.8.1. Hospital Pharmacy
    • 13.8.2. Retail Pharmacy
    • 13.8.3. Online Pharmacy
  • 13.9. Market Attractiveness, by Distribution Channel
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Drug Class
    • 13.11.2. By Disease Indication
    • 13.11.3. By Route of Administration
    • 13.11.4. By Distribution Channel
    • 13.11.5. By Country/Sub-region

14. Latin America Rheumatology Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2020-2034
    • 14.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 14.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 14.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 14.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 14.2.3. Corticosteroids
    • 14.2.4. Uric Acid Drugs
    • 14.2.5. Others
  • 14.3. Market Attractiveness, by Drug Class
  • 14.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 14.4.1. Rheumatoid Arthritis
    • 14.4.2. Osteoarthritis
    • 14.4.3. Gout
    • 14.4.4. Psoriatic Arthritis
    • 14.4.5. Ankylosing Spondylitis
    • 14.4.6. Others
  • 14.5. Market Attractiveness, by Disease Indication
  • 14.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.6.1. Parenteral Route
    • 14.6.2. Oral Route
    • 14.6.3. Topical
  • 14.7. Market Attractiveness, by Route of Administration
  • 14.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.8.1. Hospital Pharmacy
    • 14.8.2. Retail Pharmacy
    • 14.8.3. Online Pharmacy
  • 14.9. Market Attractiveness, by Distribution Channel
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Drug Class
    • 14.11.2. By Disease Indication
    • 14.11.3. By Route of Administration
    • 14.11.4. By Distribution Channel
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Rheumatology Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2020-2034
    • 15.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 15.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 15.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 15.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 15.2.3. Corticosteroids
    • 15.2.4. Uric Acid Drugs
    • 15.2.5. Others
  • 15.3. Market Attractiveness, by Drug Class
  • 15.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 15.4.1. Rheumatoid Arthritis
    • 15.4.2. Osteoarthritis
    • 15.4.3. Gout
    • 15.4.4. Psoriatic Arthritis
    • 15.4.5. Ankylosing Spondylitis
    • 15.4.6. Others
  • 15.5. Market Attractiveness, by Disease Indication
  • 15.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.6.1. Parenteral Route
    • 15.6.2. Oral Route
    • 15.6.3. Topical
  • 15.7. Market Attractiveness, by Route of Administration
  • 15.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.8.1. Hospital Pharmacy
    • 15.8.2. Retail Pharmacy
    • 15.8.3. Online Pharmacy
  • 15.9. Market Attractiveness, by Distribution Channel
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Drug Class
    • 15.11.2. By Disease Indication
    • 15.11.3. By Route of Administration
    • 15.11.4. By Distribution Channel
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. F. Hoffmann-La Roche Ltd.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. AbbVie, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Pfizer, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Takeda Pharmaceutical Company Limited
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Amgen, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Genentech, Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Novartis AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Johnson & Johnson Innovative Medicine
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Sanofi
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Merck & Co., Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 02: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 03: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 05: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 06: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 07: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 08: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 09: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 10: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 11: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 13: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 14: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 15: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 16: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 18: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 19: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 23: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 24: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 25: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 26: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 28: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 29: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Rheumatology Therapeutics Market Size (US$ Mn), by Region, 2023 and 2034
  • Figure 02: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Drug Class, 2023
  • Figure 03: Global Rheumatology Therapeutics Market Value Share, by Drug Class, 2023
  • Figure 04: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Disease Indication, 2023
  • Figure 05: Global Rheumatology Therapeutics Market Value Share, by Disease Indication, 2023
  • Figure 06: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2023
  • Figure 07: Global Rheumatology Therapeutics Market Value Share, by Route of Administration, 2023
  • Figure 08: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 09: Global Rheumatology Therapeutics Market Value Share, by Distribution Channel, 2023
  • Figure 10: Global Rheumatology Therapeutics Market Value Share, by Region, 2023
  • Figure 11: Global Rheumatology Therapeutics Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 12: Global Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 13: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 14: Global Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 15: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 16: Global Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 17: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 18: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 19: Global Rheumatology Therapeutics Market Value Share, by Distribution Channel, 2023
  • Figure 20: Global Rheumatology Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Rheumatology Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 26: North America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 27: North America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 28: North America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 29: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 30: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 31: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 32: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 33: Europe Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 37: Europe Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 38: Europe Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 39: Europe Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 40: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 41: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 42: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 43: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 44: Asia Pacific Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 48: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 49: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 52: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 53: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 54: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2034
  • Figure 55: Latin America Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 59: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 60: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 61: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 62: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 63: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 64: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 65: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 66: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 70: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 71: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 73: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 74: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 75: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 76: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034